"FDA’s revolving door reveals Pazdur as new CDER head" was originally created and published by Pharmaceutical Technology, a GlobalData owned brand.

Texas Attorney General Ken Paxton has asked a federal judge to force the makers of Tylenol to stop any advertising that the pain reliever is safe for pregnant women.

The Food and Drug Administration’s recent approval of a second generic version of the abortion pill mifepristone has left people on both sides of the reproductive rights fight scrambling to

Both The U.S. Department of Health and Human Services (HHS) and the FDA announced the appointment of Richard Pazdur, M.D., as director of the Center for Drug Evaluation and Research (CDER). 1

The FDA is warning against using certain ByHeart formula lots as they investigate over a dozen botulism cases across 10 states.

The FDA on Nov. 11 appointed Richard Pazdur, MD, as the new director of the Center for Drug Evaluation and Research.Pazdur joined the FDA in 1999 and recently served as founding director of the Oncology Center of Excellence.

According to many lawmakers, the federal government can only reopen once intoxicating hemp products have been vanquished for good.

A 26-year FDA scientist and administrator, Pazdur has headed the agency's Oncology Center of Excellence since its creation in 2017, coordinating expedited review of drugs and devices. During his tenure, the agency launched multiple initiatives to streamline oncology drug approvals, access, and labeling.

Continental Dairy Facilities Southwest LLC voluntarily initiated a recall of two butter products on October 11: Kirkland Signature Unsalted Sweet Cream Butter and Kirkland Signatu

The MarketWatch News Department was not involved in the creation of this content. FRISCO, Texas, Oct. 6, 2025 /PRNewswire-PRWeb/ -- TriCelX, Inc. ("TriCelX"), a global translational leader in evidence-based biologics, announced FDA registration of its ISO ...